SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Zelda Fitzgerald

PatientZelda Fitzgerald
Date of birth1996-07-24
IdentifiersMRN HR-ET004-SYN; SSN (made up) 000-04-8712
Document date2026-10-26
AuthorMargot Ellery, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month review: maintenance treatment, lithium monitoring, and movement check. [S]

History of Present Illness

Ms. Fitzgerald returns six weeks after her preventive visit, about six months after the episode. She has had no manic, depressive, or psychotic symptoms. She takes lithium 300 mg twice daily and aripiprazole 10 mg daily. The intrauterine system has caused only light spotting. Her HPV, HIV, hepatitis C, chlamydia and gonorrhea tests from the preventive visit were all negative. She dances about four hours a day, has a full rest day each week, eats to plan, and her periods remain regular. She sleeps eight hours and has finished a short story. She asks whether she will need both medicines for life. She has had no thoughts of suicide or self-harm. [S]

ElementDetail
Mood and psychosisNo symptoms; PHQ-9 3
MedicinesLithium 300 mg twice daily; aripiprazole 10 mg daily; levonorgestrel intrauterine system
Results from the preventive visitHPV, HIV, hepatitis C, chlamydia and gonorrhea tests negative
Dance and periodsAbout four hours a day with a rest day; periods regular

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight up slightly as planned
GenitourinaryNegativeLight spotting only; no pelvic pain; no increased urination
NeurologicalNegativeFaint tremor when tired; no restlessness or abnormal movements
PsychiatricNegativeMood steady; no manic or psychotic symptoms; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Risperidone 2 mg oral tablet, one tablet by mouth at bedtime (started in hospital)One tablet by mouth at bedtimeOral route2026-04-20 to 2026-06-08completedS
Lithium carbonate 300 mg oral capsule, one capsule by mouth twice dailyOne capsule by mouth twice dailyOral route2026-05-18activeS
Risperidone 1 mg oral tablet, one tablet by mouth at bedtime for one week, then stopOne tablet by mouth at bedtime for one weekOral route2026-06-08 to 2026-06-15completedS
Aripiprazole 10 mg oral tablet, one tablet by mouth once dailyOne tablet by mouth once dailyOral route2026-06-08activeS
Folic acid 0.4 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-09-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-26Body height165cmS
2026-10-26Body weight52.4kgS
2026-10-26Body mass index (BMI) [Ratio]19.2kg/m2S
2026-10-26Systolic blood pressure110mm[Hg]S
2026-10-26Diastolic blood pressure70mm[Hg]S
2026-10-26Heart rate68/minS
2026-10-26Respiratory rate14/minS
2026-10-26Body temperature36.5CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-26Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-26Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
2026-10-26Creatinine [Mass/volume] in Serum or Plasma0.79mg/dL0.59-1.04 mg/dLNormalS
2026-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M103mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-26Lithium [Moles/volume] in Serum or Plasma0.72mmol/LMaintenance target 0.6 to 0.8 mmol/L; above 1.2 mmol/L is above the therapeutic rangeNormalS
2026-10-26Thyrotropin [Units/volume] in Serum or Plasma3.1m[IU]/L0.45-4.5 mIU/LNormalS
2026-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 52.4 kg, BMI 19.2; blood pressure 110/70, pulse 68
NeckThyroid not enlarged
NeurologicalAIMS score 0: no abnormal movements of the face, lips, jaw, tongue, limbs, or trunk; faint fine postural tremor; no akathisia
PsychiatricEuthymic and engaged; organized; no psychotic or manic features

Problems

ProblemClinical statusVerificationCodeProvenance
First episode of psychosis with marked mood symptoms: about three weeks of little sleep, rapid speech, racing thoughts, grandiose plans and very long training days, then a voice commenting on her dancing and a belief that she was being watched and tested; tearful low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, schizoaffective disorder (bipolar type), and schizophreniform disorder or schizophrenia, depending on whether the psychosis ever occurred apart from the mood symptoms. Synthetic modern episode linked to her documented first hospitalizationresolvedprovisional F29S — Synthetic modern coding of the documented first breakdown. Unspecified psychosis is coded until the course shows how the psychosis relates to the mood symptoms; superseded at the three-month visit.
Bipolar I disorder, most recent episode manic with psychotic features, in full remission: the working diagnosis at three months, when her history, her journal, and her roommate's account (given with her consent) showed that the voice and the belief she was watched began only after weeks of manic symptoms and ended with them, with no psychosis since. Remains provisional: it would be revised to schizoaffective disorder if psychosis ever lasted two weeks or more without a mood episode. Synthetic modern episode linked to the documented breakdown and its retrospective interpretationsactiveprovisional F31.74S — Synthetic modern diagnosis made from the course; the historical diagnoses stay in the claims.
Secondary amenorrhea: no periods for about four months before admission, during very heavy dance training at a low weight (BMI 18.7), with prolactin raised on risperidone; pregnancy test negativeresolvedconfirmed N91.1S — Synthetic presenting finding linked to her documented training; resolved when her periods returned.
Acute viral gastroenteritis (vomiting and watery diarrhea for two days, roommate with the same illness), with mild dehydration; resolvedresolvedconfirmed A08.4S — Synthetic acute infection; not a historical claim.
Lithium level above the therapeutic range (1.4 mmol/L) during dehydration, with nausea and a worse fine tremor, without confusion or unsteadiness; lithium held and restarted; resolvedresolvedconfirmed T43.595AS — Synthetic medication adverse effect at a prescribed dose; ICD-10-CM classifies lithium salts with the other antipsychotics and neuroleptics.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyAntipsychotic dose, adherence, and responseEvery visitCompleted todayAripiprazole 10 mg; full adherence; taper to be reviewed with psychiatry
SurveyManic, depressive, and psychotic symptoms, and early warning signsEvery visitCompleted todayNo manic, depressive, or psychotic symptoms
ExaminationAkathisia, parkinsonism, and sedationEvery visit in the first months and after any dose changeCompleted todayNone
ExaminationAbnormal Involuntary Movement Scale (AIMS)Baseline, then every 6 monthsCompleted todayAIMS score 0 at six months; repeat in six months
ExaminationWeight and BMIEvery visit for 6 months after starting or changing an antipsychotic (CMID: baseline, 4, 8, and 12 weeks, then quarterly)Completed today52.4 kg (BMI 19.2), up 1.6 kg from intake as planned; quarterly from now
ExaminationBlood pressureBaseline, 12 weeks, then yearlyCompleted today110/70
LaboratoryFasting glucose and A1cBaseline, 12 weeks to 4 months, then yearlyUp to dateNormal at three months; next in a year
LaboratoryFasting lipid panelBaseline, 12 weeks to 4 months, then yearlyUp to dateNormal at three months; next in a year
LaboratoryLithium level (12-hour trough)5 to 7 days after starting and after any change until stable, then every 3 to 6 monthsCompleted today0.72 mmol/L; every three to six months from now
LaboratoryCreatinine and eGFR on lithiumBaseline, every 2 to 3 months for 6 months, then every 6 to 12 monthsCompleted todayCreatinine 0.79 mg/dL, eGFR 103; sodium 139, potassium 4.0 mmol/L
LaboratoryTSH on lithiumBaseline, once or twice in the first 6 months, then every 6 to 12 monthsCompleted today3.1 mIU/L; every six to twelve months from now
LaboratoryCalcium on lithiumBaseline, then yearlyUp to dateNormal at three months; next in a year
Medication safetyLithium side effects and sick-day rulesAt the start and every visitCompleted todayFaint tremor only; sick-day plan current
Medication safetyPregnancy prevention on lithium; valproate avoidedBefore starting and at each visit until a reliable method is in placeCompleted todayLevonorgestrel intrauterine system in place; folic acid daily
SurveyDepression measure (PHQ-9)Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodicallyCompleted todayPHQ-9 3, from 11 at intake: remission
SurveySuicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; safety plan and psychiatric advance directive current; the 988 Suicide & Crisis Lifeline in her phone
Self-managementSleepEvery visitCompleted todayEight hours at regular times
Self-managementEating, exercise, and periodsEvery visit while periods are absent or weight is lowCompleted todayPeriods regular; about four hours of dance a day with a rest day; SCOFF 0 at the preventive visit
Self-managementCoordinated specialty care engagementOngoing, for up to two to three yearsCompleted todayTherapist every two weeks; peer specialist monthly

Goal progress:

Guideline basis: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023); The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Psychiatry review with Dr. Langford next month about a slow aripiprazole taper. Visits every three months with lithium level, creatinine, and TSH. Calcium, glucose, A1c, lipids, and the AIMS as scheduled. [S]